ESC 365 - Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF

HFA Premium Access

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF

Session: Registries and Trial updates I

Topic: Pharmacotherapy

Speaker: Doctor S. Selvaraj (Durham, US)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Doctor Senthil Selvaraj

Duke University School of Medicine, Durham (United States of America)

2 presentations

0 follower

2 more presentations in this session

Reveal-CKD: diagnosis and management of stage 3 chronic kidney disease in patients with heart failure in italy

Speaker: Professor L. De Nicola (Naples, IT)

Impact of 2018 HFA-ESC definition of advanced HF in the HELP-HF Registry

Speaker: Doctor M. Pagnesi (Brescia, IT)

Access the full session

Registries and Trial updates I

Speakers: Doctor S. Selvaraj, Professor L. De Nicola, Doctor M. Pagnesi

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources